Published in Dig Dis Sci on January 31, 2013
Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort. PLoS One (2015) 0.76
Tocilizumab in amyloidosis-associated kidney disease secondary to inflammatory bowel diseases. Dig Dis Sci (2013) 0.75
Digitally reinforced hematoxylin-eosin polarization technique in diagnosis of rectal amyloidosis. World J Gastroenterol (2015) 0.75
Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods (1994) 13.53
Natural history and outcome in systemic AA amyloidosis. N Engl J Med (2007) 4.54
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med (2002) 4.47
Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med (1990) 3.17
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol (2003) 2.74
Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet (2001) 2.71
Review article: the evidence base for interventions used to maintain remission in Crohn's disease. Aliment Pharmacol Ther (2007) 2.70
Long-term survival in systemic amyloid A amyloidosis complicating Crohn's disease. Gastroenterology (1997) 2.18
Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol (2000) 2.11
Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut (1986) 1.44
Primary chronic interstitial nephritis in Crohn's disease. Gastroenterology (2002) 1.19
The first international standard for serum amyloid A protein (SAA). Evaluation in an international collaborative study. J Immunol Methods (1998) 1.10
Mortality and causes of death in Crohn's disease. Review of 50 years' experience in Leiden University Hospital. Gut (1990) 1.04
Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore) (1992) 1.01
Amyloidosis in regional enteritis. A report of five cases. Am J Med (1960) 0.92
Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis (2001) 0.90
Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid (2008) 0.89
Among therapy modalities of end-stage renal disease, renal transplantation improves survival in patients with amyloidosis. Transplant Proc (2006) 0.86
No improvement in survival of patients with amyloidosis associated with inflammatory rheumatic diseases -- data from the Finnish national registry for kidney diseases. J Rheumatol (2008) 0.84
Anti-TNF-alpha for treatment of amyloidosis associated with Crohn's disease. Gut (2006) 0.75
Prevalence of amyloid deposition in long standing rheumatoid arthritis in Iranian patients by abdominal subcutaneous fat biopsy and assessment of clinical and laboratory characteristics. BMC Musculoskelet Disord (2006) 0.75
Amyloidosis associated with Crohn's disease. Am J Gastroenterol (1972) 0.75
Efficacy of scheduled infliximab maintenance therapy on systemic amyloidosis associated with crohn's disease. Inflamm Bowel Dis (2011) 0.75
NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity (2004) 13.55
Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum (2004) 7.07
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med (2006) 6.17
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med (2009) 5.19
Natural history and outcome in systemic AA amyloidosis. N Engl J Med (2007) 4.54
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med (2002) 4.47
T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging (2013) 4.21
Targeting C-reactive protein for the treatment of cardiovascular disease. Nature (2006) 4.07
Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med (2013) 3.97
Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med (2003) 3.86
Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging (2013) 3.53
Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med (2007) 3.38
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35
Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol (2007) 3.12
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol (2003) 2.74
Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum (2002) 2.58
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood (2013) 2.38
In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med (2009) 2.34
Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res (2013) 2.26
Updates in cardiac amyloidosis: a review. J Am Heart Assoc (2012) 2.21
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol (2010) 2.20
Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum (2002) 2.19
Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson (2008) 2.01
Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res (2005) 1.91
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med (2015) 1.84
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature (2010) 1.81
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood (2012) 1.80
Systemic light chain amyloidosis: an update for treating physicians. Blood (2013) 1.63
Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum (2008) 1.61
Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart (2012) 1.56
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood (2006) 1.54
Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum (2003) 1.51
Familial Mediterranean fever caused by homozygous E148Q mutation complicated by Budd-Chiari syndrome and polyarteritis nodosa. Rheumatology (Oxford) (2010) 1.44
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica (2008) 1.38
Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant (2008) 1.37
An international registry on autoinflammatory diseases: the Eurofever experience. Ann Rheum Dis (2012) 1.36
Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant (2004) 1.36
Systemic amyloidosis and the gastrointestinal tract. Nat Rev Gastroenterol Hepatol (2009) 1.34
Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med (2006) 1.32
Human plasma fibrinogen is synthesized in the liver. Blood (2006) 1.27
Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N Engl J Med (2012) 1.26
Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging (2012) 1.25
Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat (2014) 1.23
Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood (2005) 1.22
Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol (2011) 1.21
Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc (2013) 1.20
AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood (2008) 1.20
Perspectives in treatment of AL amyloidosis. Br J Haematol (2007) 1.17